Methods of minimizing cancer metastasis
Inventors
Matsuda, Kazuko • Gaeta, Federico Carlos Aréjola
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12042485-B2
Publication Date
2024-07-23
Expiration Date
Abstract
A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Core Innovation
The invention relates to a method of ameliorating or minimizing metastasis of a cancer in a patient in need thereof by administering a therapeutically effective amount of ibudilast, or a pharmaceutically acceptable salt thereof. The method is directed to metastasis and specifies pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, or ovarian cancer.
The described approach includes oral administration and supports once daily dosing, with daily dosage ranges expressed as 0.1 mg to 720 mg per day. Administration can be continual and may be provided as a single dose or split into two, three, or four doses, and can be used as adjuvant therapy.
The document further describes that ibudilast may be administered in combination with one or more additional active agents and/or in combination with cancer-treatment modalities. The content provided includes chemotherapy, immunotherapy, epigenetic therapy, and liver-directed therapy, as well as surgical and radiotherapy-related modalities.
Claims Coverage
The provided claim set centers on administering ibudilast, or a pharmaceutically acceptable salt thereof, to ameliorate or minimize metastasis for specified cancer types. The coverage includes six inventive features.
Method of ameliorating or minimizing metastasis by administering ibudilast
A method of ameliorating or minimizing metastasis of a cancer in a patient in need thereof by administering a therapeutically effective amount of ibudilast, or a pharmaceutically acceptable salt thereof, wherein the cancer is pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, or ovarian cancer.
Therapeutically effective daily dosage range of ibudilast
Administering ibudilast, or a pharmaceutically acceptable salt thereof, for a daily dosage ranging from 0.1 mg to 720 mg per day.
Minimum treatment duration of ibudilast
Administering ibudilast, or a pharmaceutically acceptable salt, for at least two years.
Oral administration of ibudilast
Providing that ibudilast, or a pharmaceutically acceptable salt, is administered orally.
Combination with one or more additional active agents
Administering ibudilast together with one or more additional active agents.
Single dose or split dosing into two to four doses
Administering the therapeutically effective amount either as a single dose or split into two, three, or four doses.
Overall, the claim set centers on using ibudilast, or a pharmaceutically acceptable salt thereof, to ameliorate or minimize cancer metastasis for specified cancer types, with coverage refined by daily dosage range constraints, long-duration administration, oral route, optional combination therapy with additional active agents, and defined single-dose versus split-dose administration.
Stated Advantages
Ameliorating or minimizing cancer metastasis.
Documented Applications
Preventing, ameliorating, or minimizing metastasis of pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, or ovarian cancer by administering ibudilast, or a pharmaceutically acceptable salt thereof.
Use as adjuvant therapy.
Use in combination with chemotherapy, immunotherapy, epigenetic therapy, and liver-directed therapy, including described surgery and radiotherapy-related modalities.
Interested in licensing this patent?